Cleveland Clinic Cancer Advances
Insights from the RedirecTT-1 Study: A Potential Game-Changer for R/R Myeloma with EMD
11 Dec 2025
Shahzad Raza, MD, Hematologist at Cleveland Clinic, joins the Cancer Advances podcast to share insights from the RedirecTT-1 study. This study, presented at the 2025 American Society of Hematology (ASH) Annual Meeting, explores combining two bispecific antibodies, talquetamab and teclistamab, for patients with relapsed/refractory multiple myeloma with extramedullary disease. Listen as Dr. Raza discusses disease biology, outcomes, safety considerations and why this approach could be a major step forward for high-risk myeloma care.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
SpaceX Said to Pursue 2026 IPO
10 Dec 2025
Bloomberg Tech
Don’t Call It a Comeback
10 Dec 2025
Motley Fool Money
Japan Claims AGI, Pentagon Adopts Gemini, and MIT Designs New Medicines
10 Dec 2025
The Daily AI Show
Eric Larsen on the emergence and potential of AI in healthcare
10 Dec 2025
McKinsey on Healthcare
What it will take for AI to scale (energy, compute, talent)
10 Dec 2025
Azeem Azhar's Exponential View
Reducing Burnout and Boosting Revenue in ASCs
10 Dec 2025
Becker’s Healthcare -- Spine and Orthopedic Podcast